Search research articles
Contact Us
Filters
Showing results (81-90 of 224) with videos related to
Page
of 23
Sort By:
Leukemia
|
August 22, 2020
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
Matthew S Davids, David C Fisher, Svitlana Tyekucheva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2023
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Nehal J Lakhani, Drew Rasco, Hengbang Wang, et al.
Haematologica
|
November 21, 2024
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability
Roberta S Azevedo, Francesca Morelli, Kiyomi Mashima, et al.
Leukemia & Lymphoma
|
May 11, 2019
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
Jacob D Soumerai, Matthew S Davids, Lillian Werner, et al.
Blood Advances
|
April 10, 2024
An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL
Adam S Kittai, John N Allan, Dan James, et al.
Theranostics
|
May 14, 2025
Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies
Valentin Jacquier, Andréa Romero, Caroline Molinaro, et al.
Leukemia & Lymphoma
|
November 25, 2020
A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay
Matthew L Chase, Reid Merryman, David C Fisher, et al.
American Journal of Hematology
|
June 25, 2016
FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia
Adrian M Dubuc, Matthew S Davids, Mirela Pulluqi, et al.
Haematologica
|
August 3, 2023
Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax
Fen Zhu, Jennifer L Crombie, Wei Ni, et al.
British Journal of Haematology
|
January 14, 2015
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells
Yang Cao, Guang Yang, Zachary R Hunter, et al.
Page
of 23
Search research articles
Search
Showing results (81-90 of 224) with videos related to
Sort By:
Page
of 23
Leukemia
|
August 22, 2020
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
Matthew S Davids, David C Fisher, Svitlana Tyekucheva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2023
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Nehal J Lakhani, Drew Rasco, Hengbang Wang, et al.
Haematologica
|
November 21, 2024
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability
Roberta S Azevedo, Francesca Morelli, Kiyomi Mashima, et al.
Leukemia & Lymphoma
|
May 11, 2019
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
Jacob D Soumerai, Matthew S Davids, Lillian Werner, et al.
Blood Advances
|
April 10, 2024
An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL
Adam S Kittai, John N Allan, Dan James, et al.
Theranostics
|
May 14, 2025
Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies
Valentin Jacquier, Andréa Romero, Caroline Molinaro, et al.
Leukemia & Lymphoma
|
November 25, 2020
A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay
Matthew L Chase, Reid Merryman, David C Fisher, et al.
American Journal of Hematology
|
June 25, 2016
FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia
Adrian M Dubuc, Matthew S Davids, Mirela Pulluqi, et al.
Haematologica
|
August 3, 2023
Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax
Fen Zhu, Jennifer L Crombie, Wei Ni, et al.
British Journal of Haematology
|
January 14, 2015
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells
Yang Cao, Guang Yang, Zachary R Hunter, et al.
Page
of 23